Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics

Travere Therapeutics, Inc. (TVTX): $28.49

0.59 (+2.11%)

POWR Rating

Component Grades













Add TVTX to Watchlist
Sign Up

Industry: Biotech



in industry


  • TVTX scores best on the Value dimension, with a Value rank ahead of 79.63% of US stocks.
  • The strongest trend for TVTX is in Value, which has been heading up over the past 179 days.
  • TVTX's current lowest rank is in the Sentiment metric (where it is better than 10.02% of US stocks).

TVTX Stock Summary

  • TVTX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 152.17 -- higher than 83.89% of US-listed equities with positive expected earnings growth.
  • Of note is the ratio of Travere Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 20.25% of US stocks have a lower such ratio.
  • TVTX's price/sales ratio is 7.24; that's higher than the P/S ratio of 80.28% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Travere Therapeutics Inc, a group of peers worth examining would be FBIO, RDCM, APM, BLDP, and CLVS.
  • TVTX's SEC filings can be seen here. And to visit Travere Therapeutics Inc's official web site, go to

TVTX Valuation Summary

  • TVTX's EV/EBIT ratio is -6.7; this is 122.87% lower than that of the median Healthcare stock.
  • TVTX's price/sales ratio has moved NA NA over the prior 106 months.
  • Over the past 106 months, TVTX's price/earnings ratio has gone down 4.3.

Below are key valuation metrics over time for TVTX.

Stock Date P/S P/B P/E EV/EBIT
TVTX 2021-08-31 6.5 4.0 -5.6 -6.7
TVTX 2021-08-30 6.4 3.9 -5.5 -6.6
TVTX 2021-08-27 6.4 3.9 -5.5 -6.6
TVTX 2021-08-26 6.2 3.8 -5.3 -6.5
TVTX 2021-08-25 6.2 3.8 -5.3 -6.4
TVTX 2021-08-24 6.1 3.7 -5.2 -6.3

TVTX Growth Metrics

    Its 3 year price growth rate is now at 26.58%.
  • The 4 year cash and equivalents growth rate now stands at 188.11%.
  • Its 2 year price growth rate is now at -43.44%.
Over the past 52 months, TVTX's revenue has gone up $77,404,000.

The table below shows TVTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 227.49 -14.792 -180.091
2021-09-30 221.224 -1.785 -250.14
2021-06-30 204.146 -27.113 -237.05
2021-03-31 197.959 -40.062 -224.106
2020-12-31 198.321 -42.743 -169.431
2020-09-30 194.025 -33.365 -78.068

TVTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TVTX has a Quality Grade of C, ranking ahead of 60.91% of graded US stocks.
  • TVTX's asset turnover comes in at 0.306 -- ranking 150th of 681 Pharmaceutical Products stocks.
  • VTVT, FBRX, and NATR are the stocks whose asset turnover ratios are most correlated with TVTX.

The table below shows TVTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.306 0.969 -0.399
2021-06-30 0.291 0.968 -0.396
2021-03-31 0.289 0.968 -0.412
2020-12-31 0.311 0.969 -0.361
2020-09-30 0.304 0.970 -0.166
2020-06-30 0.303 0.967 -0.194

TVTX Price Target

For more insight on analysts targets of TVTX, see our TVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.71 Average Broker Recommendation 1.25 (Strong Buy)

TVTX Stock Price Chart Interactive Chart >

Price chart for TVTX

TVTX Price/Volume Stats

Current price $28.49 52-week high $31.65
Prev. close $27.90 52-week low $13.75
Day low $27.86 Volume 548,500
Day high $28.53 Avg. volume 771,049
50-day MA $24.39 Dividend yield N/A
200-day MA $26.49 Market Cap 1.81B

Travere Therapeutics, Inc. (TVTX) Company Bio

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.

TVTX Latest News Stream

Event/Time News Detail
Loading, please wait...

TVTX Latest Social Stream

Loading social stream, please wait...

View Full TVTX Social Stream

Latest TVTX News From Around the Web

Below are the latest news stories about Travere Therapeutics Inc that investors may wish to consider to help them evaluate TVTX as an investment opportunity.

Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2021 Results - Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q4 2021 Earnings Conference Call February 24, 2022 04:30 PM ET Company Participants Chris Cline - SVP, IR & Corporate Communications Eric Dube - CEO Jula Inrig - CMO Peter Heerma - CCO Laura Clague - CFO Bill Rote - SVP of Research & Development Conference...

SA Transcripts on Seeking Alpha | February 25, 2022

Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

NDA submission of sparsentan in IgA nephropathy on-track for first quarter 2022 Company positioned for potential NDA submission for accelerated approval of sparsentan in FSGS and combined IgA nephropathy and FSGS MAA submission mid-year 2022 Recently reported positive topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria Net product sales increased six percent to $211 million for the full year 2021 SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Trave

Yahoo | February 24, 2022

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 70,600 shares of its common stock to seven new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 45,600 shares of its common sto

Yahoo | February 14, 2022

Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information Date: Thursday, February 24, 2022Time: 4:30 p.m. ETDial-in numbers: +1 (855) 219-921

Yahoo | February 10, 2022

Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 2:20 p.m. ET. A live webcast will be available at and an archived replay will be accessible for up to 30 days. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We

Yahoo | February 9, 2022

Read More 'TVTX' Stories Here

TVTX Price Returns

1-mo 18.22%
3-mo 32.88%
6-mo 1.86%
1-year 103.21%
3-year N/A
5-year N/A
YTD -8.22%
2021 13.89%
2020 91.94%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.546 seconds.